| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1775 | 2016 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1058 | 2013 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 1056 | 2016 |
| Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma N Engl J Med 78 (6), 518-528, 2018 | 1055* | 2018 |
| Teclistamab in relapsed or refractory multiple myeloma P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, ... New England Journal of Medicine 387 (6), 495-505, 2022 | 734 | 2022 |
| Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103, 2017 | 673 | 2017 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 606 | 2010 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 600 | 2018 |
| Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ... Blood, The Journal of the American Society of Hematology 120 (8), 1589-1596, 2012 | 586 | 2012 |
| Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma J Martinez-Lopez, JJ Lahuerta, F Pepin, M González, S Barrio, R Ayala, ... Blood, The Journal of the American Society of Hematology 123 (20), 3073-3079, 2014 | 526 | 2014 |
| Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database BA Thompson, AB Spurdle, JP Plazzer, MS Greenblatt, K Akagi, ... Nature genetics 46 (2), 107-115, 2014 | 515 | 2014 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 461 | 2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 441 | 2022 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ... Journal of Clinical Oncology 39 (18), 1959-1970, 2021 | 369 | 2021 |
| Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ... Journal of Clinical Oncology 26 (35), 5775-5782, 2008 | 365 | 2008 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England Journal of Medicine 389 (4), 335-347, 2023 | 364 | 2023 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 346 | 2021 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012 | 343 | 2012 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ... Journal of Clinical Oncology 35 (25), 2900-2910, 2017 | 334 | 2017 |
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ... Journal of clinical oncology 29 (12), 1627-1633, 2011 | 294 | 2011 |
MV MateosSalamanca確認したメール アドレス: usal.es